ISRCTN90725219
Completed
Phase 1
A Phase I, prospective, double-blind, randomised, placebo-controlled, dose escalating study to assess the safety and tolerability of single and multiple oral doses of PH46A and the effect of the fasted and fed state on pharmacokinetics of PH46A in healthy volunteers
Trino Therapeutics (Ireland)0 sites96 target enrollmentMarch 11, 2014
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- lcerative colitis
- Sponsor
- Trino Therapeutics (Ireland)
- Enrollment
- 96
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy male and female volunteers aged 18\-55, as determined by medical history, physical examination, laboratory test values, vital signs and 12\-lead ECGs at screening.
- •2\. Non\-smokers from at least three months before receiving the first dose of study drug and for the duration of the study.
- •3\. Body mass index (BMI) \= 18 and \= 29 kg/m2
- •4\. Body weight \= 55 kg and \= 100 kg at screening
- •5\. Able to voluntarily provide written informed consent to participate in the study
- •6\. Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
- •7\. Female volunteers less than one year post\-menopausal must have a negative serum pregnancy test and be non\-lactating.
- •8\. Female volunteers who have been post\-menopausal for more than one year and have elevated serum follicle stimulating hormone (FSH) or are treated with hormone replacement therapy (HRT) or female volunteers who have been permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy).
- •9\. Male volunteers and female volunteers of child\-bearing potential who are sexually active must use two highly effective methods of contraception with their partners throughout the study and for 30 days after completion of the study (female volunteers) or 90 days after completion of the study (male volunteers). Acceptable methods include: condom or occlusive cap (diaphragm or cervical/ vault caps) with spermicidal foam/ gel/ film/ cream/ suppository; male sterilisation (with the appropriate post\-vasectomy documentation of the absence of sperm in the ejaculate); established use of oral, injected or implanted hormonal methods of contraception and placement of an intrauterine device or intrauterine system. True abstinence is an acceptable method only where this is already established as the volunteer?s preferred
- •and usual lifestyle.
Exclusion Criteria
- •1\. Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or current infection.
- •2\. Laboratory values at screening or baseline which are deemed to be clinically significant, unless agreed in advance by the Sponsor?s Medical Representative and Principal Investigator.
- •3\. Female volunteers who are pregnant or lactating.
- •4\. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
- •5\. Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check\-in.
- •6\. Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
- •7\. Any clinically significant illness within 30 days prior to study drug administration.
- •8\. Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol.
- •9\. Volunteers who have a history or presence of any significant drug allergy.
- •10\. Use of any prescription or over\-the\-counter medication (including vitamins, herbal and mineral supplements) within 14 days prior to study drug administration until the end of the study, with the exception of occasional paracetamol approved by the Investigator and Investigator approved contraceptives and HRT.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of egg-derived influenza vaccine and cell culture-derived influenza vaccine in healthy adult volunteersDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001240SK Chemicals100
Active, not recruiting
Not Applicable
Safety and immunogenicity study of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine 2830930A when given as 1 dose to healthy toddlers aged 12-23 months.EUCTR2011-002225-22-DEGlaxoSmithKline Biologicals
Completed
Not Applicable
A Phase 1, randomized, double-blind, controlled trial to evaluate the safety and immunogenicity of increasing intranasal doses or of three intramuscular doses of the adjuvant Gram-positive Enhancer Matrix (GEM) administered with a standard dose of trivalent inactivated influenza vaccine (TIV) antigens, compared to a standard dose of TIV antigens administered either intranasally or intramuscularly in healthy adult volunteers; followed by a randomized, double-blind, controlled evaluation of safetygriep vaccination10047438NL-OMON36678Mucosis134
Recruiting
Phase 1
A Phase 1 study to evaluate safety and tolerability of Anti-PCSK9 Product (ZRC-3306) administered subcutaneously in healthy adult human subjectsCTRI/2024/01/062126Zydus Lifesciences Ltd Formerly Cadila Healthcare Limited
Completed
Phase 1
A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human SubjectsCTRI/2021/08/035449Cadila Healthcare Ltd24